Losartan Potassium
Product Images NDC 60760-645

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 60760-645). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

645 (Losartan 645 30)

NDC 60760-645-30 is a tablets medication called Losartan that includes potassium - manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd, China. The tablets contain 50mg Potassium and the package size is 30 tablets. Additionally, it includes LOT# and EXP date for product identification. The medication is for prescription use only, and should be stored at temperatures between 15°C-30°C (59°F-86°F). If any further details on the medication are required, please refer to Use as Directed at the given website.*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

FDA Label Image

Figure 1 (Spl Image2 Figure1)

The text provides information about a study where the drug Atenolol was compared with Losartan Potassium in patients. The primary endpoint was measured as the percentage of patients at a specific risk level, and the study was conducted over a period of 66 months. The risk reduction was found to be 13% with a significance level of p=0.021.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

This text seems to be presenting data about a comparison between two drugs: Atenolol and Losartan Potassium. It suggests that Losartan Potassium may have an adjusted risk reduction of 25% compared to Atenolol, with statistical significance (p=0.001). The text also appears to show percentages of patients with fatal/non-fatal strokes over the course of some study months, ranging from 6 to 66. However, without more context or clear headings, it is difficult to interpret the information fully.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

The text describes primary composite stroke events in demographic subgroups for a clinical trial comparing the effectiveness of Losartan Potassium and Atenolol. The trial studied the effects on patients with different age groups, gender, race, presence/absence of ischemic heart disease, diabetes, history of cardiovascular diseases. The text also mentions the hazard ratio and adjusted baseline risk of patients.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

This is a graph showing the percentage of patients experiencing an event over time. The graph compares the effects of Losartan Potassium versus a placebo, with Losartan Potassium showing a risk reduction of 16.1% and a p-value of 0.022. The x-axis shows the duration of the study in months.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.